Models of β-amyloid induced Tau-pathology: the long and “folded” road to understand the mechanism
Open accessThe DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
Abstract
The amyloid cascade hypothesis has been the prevailing hypothesis in Alzheimer's Disease research, although the final and most wanted proof i.e. fully successful anti-amyloid clinical trials in patients, is still lacking. This may require a better in depth understanding of the cascade. Particularly, the exact toxic forms of Aβ and Tau, the molecular link between them and their respective contributions to the disease process need to be identified in detail. Although the lack of final proof has raised substantial criticism on the hypothesis per se, accumulating experimental evidence in in vitro models, in vivo models and from biomarkers analysis in patients supports the amyloid cascade and particularly Aβ-induced Tau-pathology, which is the focus of this review. We here discuss available models that recapitulate Aβ-induced Tau-pathology and review some potential underlying mechanisms. The availability and diversity of these models that mimic the amyloid cascade partially or more complete, provide tools to study remaining questions, which are crucial for development of therapeutic strategies for Alzheimer's Disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Amyloid cascade hypothesis in transgenic mice with combined amyloid and Tau pathology (left panel). Hippocampal (HC; CA1) and cortical (Cx) immunohistochemical staining for amyloid plaques (anti-Aβ, WO2), astrocytes (GFAP), microglia (Iba1), P-GSK3 (GSK3pT216/279), P-Tau (anti-pTau, AT-8) and NeuN for cortical/hippocampal atrophy (all images are 20×, except NeuN at 4×) is presented in transgenic mice expressing mutant APP/PS1 and mutant Tau [55]. These mice were generated by crossing mutant APP/PS1 and mutant Tau mice, respectively denoted as F+/T- (5xFAD; [59]) and F-/T+(TauP301S; [60]). Of note, AT-8 staining was optimized to match Gallyas silver staining patterns, hence representing NFTs (data not shown). Main pathological features found in F+/T+ mice (right panel). Immunolabeling with anti-Aβ (WO2), showing no changes in amyloid plaque load in the cortex of F+/T + and F+/T- mice (upper panel, 4× and 20×); Aggravation of Tau-pathology, anti-pTau (AT-8) staining (NFT), in hippocampal CA1 region and cortex of F+/T+ compared to F-/T+ parental strain transgenic mice (middle panel, 20×); anti-neuronal nuclear staining (NeuN) showing decreased cortical and hippocampal area in F+/T+ compared to F-/T- mice (lower panel, 4×).](https://figures.cochat.ai/paper-figures/3f257cb307a0411084a4d0f819275560/models-of-amyloid-induced-tau-pathology-the-long-and-folded-road-to-understand-figure-1.jpg)
![Figure 2 Graphical representation of the regional distribution of amyloid plaques and NFTs in hippocampus and entorhinal cortex (upper panel, hippocampal-entorhinal connectivity map modified after Deng et al. [61]). Analysis of the relation between amyloid plaques (anti-Aβ, WO2, green) and Tau-pathology (anti-pTau, AT-8, red) in entorhinal cortex (lower left panel) and hippocampus (lower right panel) of F+/T+ transgenic mice, with details of the regional distribution of amyloid- and Tau-pathology for each of these regions.](https://figures.cochat.ai/paper-figures/0aa8b5487d68433290112eada7033252/models-of-amyloid-induced-tau-pathology-the-long-and-folded-road-to-understand-figure-2.jpg)
![Figure 3 Schematic presentation of proposed mechanisms involved in Aβ-induced Tau-aggregation as discussed in this review (elements in panel I. and II. modified from Servier Medical Art; elements in panel III. modified from Jucker and Walker [76] , Thal et al. [75] , Braak and Braak [73] ).](https://figures.cochat.ai/paper-figures/98345af2908748e4a275b0a91fce75eb/models-of-amyloid-induced-tau-pathology-the-long-and-folded-road-to-understand-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“aggregated Aβ peptides may induce tau hyperphosphorylation both in vitro and in vivo (6, 26)”
From Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease (2020) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“These observations support the idea that Aβ and Tau act together and that Aβ is upstream of Tau [114,115], positioning Aβ as the initiator and Tau as the executor in the pathogenetic process [116].”
From Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models (2020) · cites this paper as [116]
The cited source says what the claim attributes to it.
In the citing paper
“A growing body of evidence highlights the critical interplay between these pathologies, potentially through synapses and glial activation, that drives disease progression.”
From Unique transcriptomic alterations in 5XFAD;PS19 mouse model identify glial lipid dysregulation and coordinated microglial–oligodendrocyte responses (2026) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Both amyloid-beta and tau are believed to synergistically drive neurodegenerative processes involved in AD (Bloom, 2014; Lloret et al., 2015; Stancu, Vasconcelos, Terwel, & Dewachter, 2014).”
From Functional and structural connectome properties in the 5XFAD transgenic mouse model of Alzheimer’s disease (2018) · cites this paper as Stancu, Vasconcelos, Terwel, & Dewachter, 2014
In the citing paper
“Furthermore, the pathophysiology of Alzheimer’s disease includes the degeneration of neurons at vulnerable spots in the brain such as thehippocampus and cortex region [150,151,152].”
From Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer’s Disease Therapy (2021) · cites this paper as [152]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“Progression of Tau-pathology occurs in a stereotypic way, which has been accepted as standard for staging the disease process [5,73,74].”
BackgroundThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 5×
“As elegant discussions and in depth reviews of patient data are provided by others, we restrict the discussion here to a concise description of the integrated hypothesis which reconciles these discussions [1,62-72].”
BackgroundInfluentialAlzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 2×
“Mechanisms involved in Aβ-induced synaptic dysfunction are under meticulous analysis (excellently reviewed in [92-96]).”
BackgroundJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 1×
“Identification of alpha-secretase (ADAM10 [10], TACE), beta-secretase (BACE1 [11]) and gamma-secretase (as a complex containing aph1, pen2, nicastrin, PS1 [12,13]) and the analysis of their potential as therapeutic targets”
BackgroundOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“(5xFAD; [59]) and F-/T+(TauP301S; [60]).”
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · cited 1×
“Intriguingly, Aβ accumulation in AD patients occurs temporally and anatomically distinct from Tauopathy and is able to accelerate Tau pathology and to facilitate neurodegeneration [63,67,71,73,75].”
Background
Cited by
Stancu, I.-C., Cremers, N., Vanrusselt, H., Couturier, J., Vanoosthuyse, A., Kessels, S., Lodder, C., Brône, B., Huaux, F., Octave, J.-N., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-01957-y · Cited by 447
Self-citationSchwarz, A. J., Yu, P., Miller, B. B., Shcherbinin, S., Dickson, J., Navitsky, M., Joshi, A. D., Devous, M. D., & Mintun, M. S. (2016) · Brain · doi:10.1093/brain/aww023 · Cited by 425
Molecular Pathogenesis of Alzheimer's Disease: An Update
Sanabria-Castro, A., Alvarado-Echeverría, I., & Monge-Bonilla, C. (2017) · Annals of Neurosciences · doi:10.1159/000464422 · Cited by 418
Janelidze, S., Berron, D., Smith, R., Strandberg, O., Proctor, N. K., Dage, J. L., Stomrud, E., Palmqvist, S., Mattsson-Carlgren, N., & Hansson, O. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.4201 · Cited by 381
Mattsson-Carlgren, N., Andersson, E., Janelidze, S., Ossenkoppele, R., Insel, P., Strandberg, O., Zetterberg, H., Rosen, H. J., Rabinovici, G., Chai, X., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz2387 · Cited by 359
“Several possibilities exist, including that A may induce tau alterations through specific binding to receptors (or nonspecific binding to lipid membranes) ( 4 ).”
Influential
Metadata
- Authors
- Stancu, I.-C., Vasconcelos, B., Terwel, D., & Dewachter, I.
- Affiliations
- UCLouvain (BE)
- Corresponding author
- Dewachter, Ilse
- Venue
- Molecular Neurodegeneration
- Published
- 2014-11-18
- Volume
- 9
- Issue
- 1
- Pages
- 51-51
- ISSN
- 1750-1326 (ISSN-L)
- PMC
- PMC4255655
- OpenAlex
- W2120402847
- Cited by
- 256
- References
- 131
- Citations by year
- 2026: 8 · 2025: 17 · 2024: 15 · 2023: 27 · 2022: 20 · 2021: 24 · 2020: 33 · 2019: 19 · 2018: 27 · 2017: 22 · 2016: 32 · 2015: 12
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Molecular Neurodegeneration (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- Document Server@UHasselt (UHasselt) (submittedVersion, cc-by)
- Funders
- European Commission (305299)
- Fonds De La Recherche Scientifique - FNRS
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid hypothesis, amyloid-beta, tau pathology, animal models of Alzheimer's disease, in vitro model, in vivo models, disease mechanisms
- MeSH terms
- Alzheimer Disease, Animals, Humans, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Models of β-amyloid induced Tau-pathology: the long and “folded” road to understand the mechanism. https://app.cochat.ai/papers/10.1186/1750-1326-9-51
- The paper
- Stancu, I.-C., Vasconcelos, B., Terwel, D., & Dewachter, I. (2014). Models of β-amyloid induced Tau-pathology: the long and “folded” road to understand the mechanism. Molecular Neurodegeneration. https://doi.org/10.1186/1750-1326-9-51
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.